ACT Venture Partners
ACT Venture Partners news

RS Research secures $12 million in Series A funding led by GEN İlaç

Biotechnology startup RS Research has announced the completion of its $12 million Series A funding round. The investment is led by GEN İlaç with participation from One Life Ventures (Istanbul Portfolio Management) and Eczacıbaşı Momentum.

Founded by Prof. Dr. Rana Sanyal and Sena Nomak, RS Research is developing novel targeted drug delivery technology that aims to reduce the side effects of chemotherapy drugs while increasing their effectiveness. ACT Venture Partners is backing RS Research since their first investment round in 2017 and new funding will be used to accelerate the clinical development processes of drug candidates in the company’s portfolio.
(TR) Read more about the story here.
(ENG) Read more about the story here.